nodes	percent_of_prediction	percent_of_DWPC	metapath
Avanafil—CYP3A4—prostate cancer	0.286	1	CbGaD
Avanafil—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0865	0.207	CbGbCtD
Avanafil—CYP3A4—Bicalutamide—prostate cancer	0.0454	0.109	CbGbCtD
Avanafil—CYP3A4—Estramustine—prostate cancer	0.0422	0.101	CbGbCtD
Avanafil—CYP3A4—Flutamide—prostate cancer	0.0377	0.09	CbGbCtD
Avanafil—CYP3A4—Abiraterone—prostate cancer	0.0377	0.09	CbGbCtD
Avanafil—CYP3A4—Cabazitaxel—prostate cancer	0.0279	0.0666	CbGbCtD
Avanafil—CYP3A4—Estrone—prostate cancer	0.0272	0.0651	CbGbCtD
Avanafil—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0243	0.058	CbGbCtD
Avanafil—PDE5A—penis—prostate cancer	0.0201	0.459	CbGeAlD
Avanafil—CYP3A4—Conjugated Estrogens—prostate cancer	0.0178	0.0426	CbGbCtD
Avanafil—CYP3A4—Mitoxantrone—prostate cancer	0.0162	0.0387	CbGbCtD
Avanafil—CYP3A4—Estradiol—prostate cancer	0.0156	0.0374	CbGbCtD
Avanafil—CYP3A4—Prednisone—prostate cancer	0.0134	0.0321	CbGbCtD
Avanafil—CYP3A4—Etoposide—prostate cancer	0.0102	0.0244	CbGbCtD
Avanafil—CYP3A4—Docetaxel—prostate cancer	0.00934	0.0223	CbGbCtD
Avanafil—CYP3A4—Doxorubicin—prostate cancer	0.00696	0.0166	CbGbCtD
Avanafil—PDE5A—prostate gland—prostate cancer	0.0048	0.11	CbGeAlD
Avanafil—CYP3A4—urine—prostate cancer	0.00417	0.0953	CbGeAlD
Avanafil—PDE5A—epithelium—prostate cancer	0.00353	0.0806	CbGeAlD
Avanafil—PDE5A—renal system—prostate cancer	0.00327	0.0748	CbGeAlD
Avanafil—PDE5A—urethra—prostate cancer	0.00322	0.0735	CbGeAlD
Avanafil—PDE5A—testis—prostate cancer	0.00212	0.0483	CbGeAlD
Avanafil—PDE5A—lymph node—prostate cancer	0.00153	0.035	CbGeAlD
Avanafil—CYP3A4—renal system—prostate cancer	0.00102	0.0233	CbGeAlD
Avanafil—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000154	0.0044	CbGpPWpGaD
Avanafil—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000153	0.00437	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.000153	0.00435	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—THBS1—prostate cancer	0.000152	0.00435	CbGpPWpGaD
Avanafil—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000152	0.00433	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PRKCZ—prostate cancer	0.000148	0.00421	CbGpPWpGaD
Avanafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000147	0.00419	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000143	0.00408	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000141	0.00402	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000138	0.00394	CbGpPWpGaD
Avanafil—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.000134	0.00381	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.000133	0.00378	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000131	0.00374	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000129	0.00369	CbGpPWpGaD
Avanafil—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000128	0.00365	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000126	0.00359	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PRKCQ—prostate cancer	0.000125	0.00358	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000125	0.00358	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—PLAUR—prostate cancer	0.000124	0.00354	CbGpPWpGaD
Avanafil—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000123	0.0035	CbGpPWpGaD
Avanafil—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.000118	0.00337	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000117	0.00334	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VAV3—prostate cancer	0.000115	0.00328	CbGpPWpGaD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000112	0.00319	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—ITPR1—prostate cancer	0.000112	0.00318	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000108	0.00307	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000106	0.00303	CbGpPWpGaD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.000104	0.00298	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000103	0.00294	CbGpPWpGaD
Avanafil—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000101	0.00288	CbGpPWpGaD
Avanafil—Nausea—Goserelin—prostate cancer	9.93e-05	0.000458	CcSEcCtD
Avanafil—PDE5A—Hemostasis—ITGB3—prostate cancer	9.87e-05	0.00282	CbGpPWpGaD
Avanafil—Angina pectoris—Epirubicin—prostate cancer	9.87e-05	0.000455	CcSEcCtD
Avanafil—Nausea—Conjugated Estrogens—prostate cancer	9.84e-05	0.000454	CcSEcCtD
Avanafil—Back pain—Capecitabine—prostate cancer	9.8e-05	0.000452	CcSEcCtD
Avanafil—Breast disorder—Doxorubicin—prostate cancer	9.8e-05	0.000452	CcSEcCtD
Avanafil—Body temperature increased—Mitoxantrone—prostate cancer	9.77e-05	0.00045	CcSEcCtD
Avanafil—Bronchitis—Epirubicin—prostate cancer	9.74e-05	0.000449	CcSEcCtD
Avanafil—Muscle spasms—Capecitabine—prostate cancer	9.74e-05	0.000449	CcSEcCtD
Avanafil—Nasopharyngitis—Doxorubicin—prostate cancer	9.7e-05	0.000447	CcSEcCtD
Avanafil—Eye disorder—Prednisone—prostate cancer	9.69e-05	0.000447	CcSEcCtD
Avanafil—Flushing—Prednisone—prostate cancer	9.62e-05	0.000444	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	9.61e-05	0.00274	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	9.61e-05	0.00274	CbGpPWpGaD
Avanafil—Hypotension—Etoposide—prostate cancer	9.6e-05	0.000443	CcSEcCtD
Avanafil—Gastritis—Doxorubicin—prostate cancer	9.6e-05	0.000443	CcSEcCtD
Avanafil—Alanine aminotransferase increased—Doxorubicin—prostate cancer	9.56e-05	0.000441	CcSEcCtD
Avanafil—Vision blurred—Capecitabine—prostate cancer	9.55e-05	0.00044	CcSEcCtD
Avanafil—Asthenia—Estradiol—prostate cancer	9.51e-05	0.000439	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	9.5e-05	0.00271	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	9.47e-05	0.0027	CbGpPWpGaD
Avanafil—Upper respiratory tract infection—Epirubicin—prostate cancer	9.41e-05	0.000434	CcSEcCtD
Avanafil—Angiopathy—Prednisone—prostate cancer	9.41e-05	0.000434	CcSEcCtD
Avanafil—Pruritus—Estradiol—prostate cancer	9.38e-05	0.000433	CcSEcCtD
Avanafil—Influenza—Doxorubicin—prostate cancer	9.37e-05	0.000432	CcSEcCtD
Avanafil—Immune system disorder—Prednisone—prostate cancer	9.36e-05	0.000432	CcSEcCtD
Avanafil—Pollakiuria—Epirubicin—prostate cancer	9.36e-05	0.000431	CcSEcCtD
Avanafil—Palpitations—Docetaxel—prostate cancer	9.25e-05	0.000426	CcSEcCtD
Avanafil—Weight increased—Epirubicin—prostate cancer	9.22e-05	0.000425	CcSEcCtD
Avanafil—Somnolence—Etoposide—prostate cancer	9.14e-05	0.000421	CcSEcCtD
Avanafil—Cough—Docetaxel—prostate cancer	9.13e-05	0.000421	CcSEcCtD
Avanafil—Angina pectoris—Doxorubicin—prostate cancer	9.13e-05	0.000421	CcSEcCtD
Avanafil—Vertigo—Capecitabine—prostate cancer	9.1e-05	0.00042	CcSEcCtD
Avanafil—Mental disorder—Prednisone—prostate cancer	9.08e-05	0.000419	CcSEcCtD
Avanafil—Diarrhoea—Estradiol—prostate cancer	9.07e-05	0.000418	CcSEcCtD
Avanafil—Hypertension—Docetaxel—prostate cancer	9.03e-05	0.000417	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTM3—prostate cancer	9.03e-05	0.00258	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	9.03e-05	0.00258	CbGpPWpGaD
Avanafil—Infestation NOS—Epirubicin—prostate cancer	9.03e-05	0.000416	CcSEcCtD
Avanafil—Infestation—Epirubicin—prostate cancer	9.03e-05	0.000416	CcSEcCtD
Avanafil—Malnutrition—Prednisone—prostate cancer	9.02e-05	0.000416	CcSEcCtD
Avanafil—Bronchitis—Doxorubicin—prostate cancer	9.01e-05	0.000416	CcSEcCtD
Avanafil—Palpitations—Capecitabine—prostate cancer	8.95e-05	0.000413	CcSEcCtD
Avanafil—Myalgia—Docetaxel—prostate cancer	8.91e-05	0.000411	CcSEcCtD
Avanafil—Chest pain—Docetaxel—prostate cancer	8.91e-05	0.000411	CcSEcCtD
Avanafil—Arthralgia—Docetaxel—prostate cancer	8.91e-05	0.000411	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	8.91e-05	0.00254	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	8.91e-05	0.00254	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Etoposide—prostate cancer	8.87e-05	0.000409	CcSEcCtD
Avanafil—Asthenia—Mitoxantrone—prostate cancer	8.86e-05	0.000409	CcSEcCtD
Avanafil—Fatigue—Etoposide—prostate cancer	8.86e-05	0.000408	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	8.85e-05	0.000408	CcSEcCtD
Avanafil—Cough—Capecitabine—prostate cancer	8.84e-05	0.000408	CcSEcCtD
Avanafil—Constipation—Etoposide—prostate cancer	8.79e-05	0.000405	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	8.78e-05	0.00251	CbGpPWpGaD
Avanafil—Urinary tract infection—Epirubicin—prostate cancer	8.78e-05	0.000405	CcSEcCtD
Avanafil—Dizziness—Estradiol—prostate cancer	8.77e-05	0.000404	CcSEcCtD
Avanafil—Hypertension—Capecitabine—prostate cancer	8.75e-05	0.000403	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	8.71e-05	0.00249	CbGpPWpGaD
Avanafil—Dry mouth—Docetaxel—prostate cancer	8.71e-05	0.000402	CcSEcCtD
Avanafil—Upper respiratory tract infection—Doxorubicin—prostate cancer	8.71e-05	0.000402	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PLAU—prostate cancer	8.69e-05	0.00248	CbGpPWpGaD
Avanafil—Pollakiuria—Doxorubicin—prostate cancer	8.66e-05	0.000399	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	8.65e-05	0.00247	CbGpPWpGaD
Avanafil—Chest pain—Capecitabine—prostate cancer	8.63e-05	0.000398	CcSEcCtD
Avanafil—Arthralgia—Capecitabine—prostate cancer	8.63e-05	0.000398	CcSEcCtD
Avanafil—Myalgia—Capecitabine—prostate cancer	8.63e-05	0.000398	CcSEcCtD
Avanafil—Haematuria—Epirubicin—prostate cancer	8.61e-05	0.000397	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.57e-05	0.000395	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—NAT1—prostate cancer	8.56e-05	0.00244	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	8.56e-05	0.00244	CbGpPWpGaD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	8.54e-05	0.00244	CbGpPWpGaD
Avanafil—Weight increased—Doxorubicin—prostate cancer	8.53e-05	0.000393	CcSEcCtD
Avanafil—Epistaxis—Epirubicin—prostate cancer	8.52e-05	0.000393	CcSEcCtD
Avanafil—Vision blurred—Prednisone—prostate cancer	8.5e-05	0.000392	CcSEcCtD
Avanafil—PDE5A—Hemostasis—CAV1—prostate cancer	8.49e-05	0.00242	CbGpPWpGaD
Avanafil—Infection—Docetaxel—prostate cancer	8.48e-05	0.000391	CcSEcCtD
Avanafil—Sinusitis—Epirubicin—prostate cancer	8.47e-05	0.000391	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	8.47e-05	0.00242	CbGpPWpGaD
Avanafil—Diarrhoea—Mitoxantrone—prostate cancer	8.45e-05	0.00039	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	8.44e-05	0.00241	CbGpPWpGaD
Avanafil—Dry mouth—Capecitabine—prostate cancer	8.44e-05	0.000389	CcSEcCtD
Avanafil—Vomiting—Estradiol—prostate cancer	8.43e-05	0.000389	CcSEcCtD
Avanafil—Nervous system disorder—Docetaxel—prostate cancer	8.38e-05	0.000386	CcSEcCtD
Avanafil—Rash—Estradiol—prostate cancer	8.36e-05	0.000385	CcSEcCtD
Avanafil—Infestation NOS—Doxorubicin—prostate cancer	8.36e-05	0.000385	CcSEcCtD
Avanafil—Infestation—Doxorubicin—prostate cancer	8.36e-05	0.000385	CcSEcCtD
Avanafil—Dermatitis—Estradiol—prostate cancer	8.35e-05	0.000385	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	8.35e-05	0.00238	CbGpPWpGaD
Avanafil—Tachycardia—Docetaxel—prostate cancer	8.33e-05	0.000384	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	8.32e-05	0.00237	CbGpPWpGaD
Avanafil—Headache—Estradiol—prostate cancer	8.31e-05	0.000383	CcSEcCtD
Avanafil—Skin disorder—Docetaxel—prostate cancer	8.3e-05	0.000382	CcSEcCtD
Avanafil—Agitation—Prednisone—prostate cancer	8.29e-05	0.000382	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	8.24e-05	0.00235	CbGpPWpGaD
Avanafil—Infection—Capecitabine—prostate cancer	8.21e-05	0.000379	CcSEcCtD
Avanafil—Body temperature increased—Etoposide—prostate cancer	8.12e-05	0.000375	CcSEcCtD
Avanafil—Urinary tract infection—Doxorubicin—prostate cancer	8.12e-05	0.000375	CcSEcCtD
Avanafil—Nervous system disorder—Capecitabine—prostate cancer	8.11e-05	0.000374	CcSEcCtD
Avanafil—Vertigo—Prednisone—prostate cancer	8.11e-05	0.000374	CcSEcCtD
Avanafil—Tachycardia—Capecitabine—prostate cancer	8.07e-05	0.000372	CcSEcCtD
Avanafil—Skin disorder—Capecitabine—prostate cancer	8.03e-05	0.00037	CcSEcCtD
Avanafil—Urinary tract disorder—Epirubicin—prostate cancer	8.01e-05	0.000369	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	8e-05	0.00228	CbGpPWpGaD
Avanafil—Oedema peripheral—Epirubicin—prostate cancer	7.99e-05	0.000368	CcSEcCtD
Avanafil—Hypotension—Docetaxel—prostate cancer	7.98e-05	0.000368	CcSEcCtD
Avanafil—Haematuria—Doxorubicin—prostate cancer	7.97e-05	0.000367	CcSEcCtD
Avanafil—Connective tissue disorder—Epirubicin—prostate cancer	7.97e-05	0.000367	CcSEcCtD
Avanafil—Urethral disorder—Epirubicin—prostate cancer	7.95e-05	0.000366	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	7.89e-05	0.00225	CbGpPWpGaD
Avanafil—Epistaxis—Doxorubicin—prostate cancer	7.88e-05	0.000363	CcSEcCtD
Avanafil—Nausea—Estradiol—prostate cancer	7.88e-05	0.000363	CcSEcCtD
Avanafil—Vomiting—Mitoxantrone—prostate cancer	7.85e-05	0.000362	CcSEcCtD
Avanafil—Sinusitis—Doxorubicin—prostate cancer	7.84e-05	0.000361	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	7.83e-05	0.00223	CbGpPWpGaD
Avanafil—Hypertension—Prednisone—prostate cancer	7.79e-05	0.000359	CcSEcCtD
Avanafil—Rash—Mitoxantrone—prostate cancer	7.79e-05	0.000359	CcSEcCtD
Avanafil—Dermatitis—Mitoxantrone—prostate cancer	7.78e-05	0.000359	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.78e-05	0.000359	CcSEcCtD
Avanafil—Headache—Mitoxantrone—prostate cancer	7.74e-05	0.000357	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CG—prostate cancer	7.73e-05	0.00221	CbGpPWpGaD
Avanafil—Hypotension—Capecitabine—prostate cancer	7.73e-05	0.000356	CcSEcCtD
Avanafil—Insomnia—Docetaxel—prostate cancer	7.72e-05	0.000356	CcSEcCtD
Avanafil—Myalgia—Prednisone—prostate cancer	7.68e-05	0.000354	CcSEcCtD
Avanafil—Arthralgia—Prednisone—prostate cancer	7.68e-05	0.000354	CcSEcCtD
Avanafil—PDE5A—Hemostasis—EGF—prostate cancer	7.65e-05	0.00218	CbGpPWpGaD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.63e-05	0.000352	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	7.62e-05	0.00217	CbGpPWpGaD
Avanafil—Somnolence—Docetaxel—prostate cancer	7.59e-05	0.00035	CcSEcCtD
Avanafil—Eye disorder—Epirubicin—prostate cancer	7.58e-05	0.000349	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.53e-05	0.000347	CcSEcCtD
Avanafil—Cardiac disorder—Epirubicin—prostate cancer	7.52e-05	0.000347	CcSEcCtD
Avanafil—Flushing—Epirubicin—prostate cancer	7.52e-05	0.000347	CcSEcCtD
Avanafil—Dyspepsia—Docetaxel—prostate cancer	7.52e-05	0.000347	CcSEcCtD
Avanafil—Insomnia—Capecitabine—prostate cancer	7.48e-05	0.000345	CcSEcCtD
Avanafil—Urinary tract disorder—Doxorubicin—prostate cancer	7.41e-05	0.000342	CcSEcCtD
Avanafil—Oedema peripheral—Doxorubicin—prostate cancer	7.39e-05	0.000341	CcSEcCtD
Avanafil—Gastrointestinal disorder—Docetaxel—prostate cancer	7.37e-05	0.00034	CcSEcCtD
Avanafil—Asthenia—Etoposide—prostate cancer	7.37e-05	0.00034	CcSEcCtD
Avanafil—Connective tissue disorder—Doxorubicin—prostate cancer	7.37e-05	0.00034	CcSEcCtD
Avanafil—Fatigue—Docetaxel—prostate cancer	7.36e-05	0.000339	CcSEcCtD
Avanafil—Angiopathy—Epirubicin—prostate cancer	7.36e-05	0.000339	CcSEcCtD
Avanafil—Urethral disorder—Doxorubicin—prostate cancer	7.35e-05	0.000339	CcSEcCtD
Avanafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	7.35e-05	0.0021	CbGpPWpGaD
Avanafil—Nausea—Mitoxantrone—prostate cancer	7.34e-05	0.000338	CcSEcCtD
Avanafil—Immune system disorder—Epirubicin—prostate cancer	7.32e-05	0.000338	CcSEcCtD
Avanafil—Infection—Prednisone—prostate cancer	7.32e-05	0.000337	CcSEcCtD
Avanafil—Mediastinal disorder—Epirubicin—prostate cancer	7.31e-05	0.000337	CcSEcCtD
Avanafil—Constipation—Docetaxel—prostate cancer	7.3e-05	0.000337	CcSEcCtD
Avanafil—Dyspepsia—Capecitabine—prostate cancer	7.28e-05	0.000336	CcSEcCtD
Avanafil—Pruritus—Etoposide—prostate cancer	7.27e-05	0.000335	CcSEcCtD
Avanafil—Nervous system disorder—Prednisone—prostate cancer	7.22e-05	0.000333	CcSEcCtD
Avanafil—Tachycardia—Prednisone—prostate cancer	7.19e-05	0.000331	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	7.18e-05	0.00205	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—CREBBP—prostate cancer	7.17e-05	0.00205	CbGpPWpGaD
Avanafil—Skin disorder—Prednisone—prostate cancer	7.15e-05	0.00033	CcSEcCtD
Avanafil—Gastrointestinal disorder—Capecitabine—prostate cancer	7.14e-05	0.000329	CcSEcCtD
Avanafil—Fatigue—Capecitabine—prostate cancer	7.13e-05	0.000329	CcSEcCtD
Avanafil—Mental disorder—Epirubicin—prostate cancer	7.1e-05	0.000328	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	7.1e-05	0.00203	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IGF1—prostate cancer	7.08e-05	0.00202	CbGpPWpGaD
Avanafil—Constipation—Capecitabine—prostate cancer	7.07e-05	0.000326	CcSEcCtD
Avanafil—Malnutrition—Epirubicin—prostate cancer	7.06e-05	0.000325	CcSEcCtD
Avanafil—Diarrhoea—Etoposide—prostate cancer	7.03e-05	0.000324	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	7.02e-05	0.002	CbGpPWpGaD
Avanafil—Eye disorder—Doxorubicin—prostate cancer	7.01e-05	0.000323	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	7.01e-05	0.002	CbGpPWpGaD
Avanafil—Cardiac disorder—Doxorubicin—prostate cancer	6.96e-05	0.000321	CcSEcCtD
Avanafil—Flushing—Doxorubicin—prostate cancer	6.96e-05	0.000321	CcSEcCtD
Avanafil—Back pain—Epirubicin—prostate cancer	6.83e-05	0.000315	CcSEcCtD
Avanafil—Angiopathy—Doxorubicin—prostate cancer	6.81e-05	0.000314	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CD—prostate cancer	6.8e-05	0.00194	CbGpPWpGaD
Avanafil—Dizziness—Etoposide—prostate cancer	6.8e-05	0.000313	CcSEcCtD
Avanafil—Muscle spasms—Epirubicin—prostate cancer	6.79e-05	0.000313	CcSEcCtD
Avanafil—Immune system disorder—Doxorubicin—prostate cancer	6.78e-05	0.000312	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	6.77e-05	0.00193	CbGpPWpGaD
Avanafil—Mediastinal disorder—Doxorubicin—prostate cancer	6.76e-05	0.000312	CcSEcCtD
Avanafil—Body temperature increased—Docetaxel—prostate cancer	6.75e-05	0.000311	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	6.73e-05	0.00192	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SERPINE1—prostate cancer	6.73e-05	0.00192	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Prednisone—prostate cancer	6.71e-05	0.000309	CcSEcCtD
Avanafil—Insomnia—Prednisone—prostate cancer	6.66e-05	0.000307	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	6.66e-05	0.0019	CbGpPWpGaD
Avanafil—Vision blurred—Epirubicin—prostate cancer	6.65e-05	0.000307	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	6.64e-05	0.00189	CbGpPWpGaD
Avanafil—Mental disorder—Doxorubicin—prostate cancer	6.57e-05	0.000303	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	6.57e-05	0.00187	CbGpPWpGaD
Avanafil—Body temperature increased—Capecitabine—prostate cancer	6.54e-05	0.000301	CcSEcCtD
Avanafil—Vomiting—Etoposide—prostate cancer	6.53e-05	0.000301	CcSEcCtD
Avanafil—Malnutrition—Doxorubicin—prostate cancer	6.53e-05	0.000301	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	6.49e-05	0.00185	CbGpPWpGaD
Avanafil—Agitation—Epirubicin—prostate cancer	6.49e-05	0.000299	CcSEcCtD
Avanafil—Dyspepsia—Prednisone—prostate cancer	6.48e-05	0.000299	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	6.48e-05	0.00185	CbGpPWpGaD
Avanafil—Rash—Etoposide—prostate cancer	6.48e-05	0.000299	CcSEcCtD
Avanafil—Dermatitis—Etoposide—prostate cancer	6.47e-05	0.000298	CcSEcCtD
Avanafil—Headache—Etoposide—prostate cancer	6.44e-05	0.000297	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	6.42e-05	0.00183	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—NOS3—prostate cancer	6.42e-05	0.00183	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	6.4e-05	0.00183	CbGpPWpGaD
Avanafil—Fatigue—Prednisone—prostate cancer	6.35e-05	0.000293	CcSEcCtD
Avanafil—Vertigo—Epirubicin—prostate cancer	6.34e-05	0.000292	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	6.33e-05	0.00181	CbGpPWpGaD
Avanafil—Back pain—Doxorubicin—prostate cancer	6.32e-05	0.000291	CcSEcCtD
Avanafil—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	6.31e-05	0.0018	CbGpPWpGaD
Avanafil—Constipation—Prednisone—prostate cancer	6.3e-05	0.00029	CcSEcCtD
Avanafil—Muscle spasms—Doxorubicin—prostate cancer	6.28e-05	0.000289	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	6.25e-05	0.00178	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—JAK2—prostate cancer	6.24e-05	0.00178	CbGpPWpGaD
Avanafil—Palpitations—Epirubicin—prostate cancer	6.24e-05	0.000288	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	6.18e-05	0.00176	CbGpPWpGaD
Avanafil—Cough—Epirubicin—prostate cancer	6.16e-05	0.000284	CcSEcCtD
Avanafil—Vision blurred—Doxorubicin—prostate cancer	6.15e-05	0.000284	CcSEcCtD
Avanafil—Asthenia—Docetaxel—prostate cancer	6.13e-05	0.000283	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	6.11e-05	0.00174	CbGpPWpGaD
Avanafil—Nausea—Etoposide—prostate cancer	6.1e-05	0.000281	CcSEcCtD
Avanafil—Hypertension—Epirubicin—prostate cancer	6.09e-05	0.000281	CcSEcCtD
Avanafil—Pruritus—Docetaxel—prostate cancer	6.04e-05	0.000279	CcSEcCtD
Avanafil—Chest pain—Epirubicin—prostate cancer	6.01e-05	0.000277	CcSEcCtD
Avanafil—Arthralgia—Epirubicin—prostate cancer	6.01e-05	0.000277	CcSEcCtD
Avanafil—Myalgia—Epirubicin—prostate cancer	6.01e-05	0.000277	CcSEcCtD
Avanafil—Agitation—Doxorubicin—prostate cancer	6e-05	0.000277	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.97e-05	0.000275	CcSEcCtD
Avanafil—Asthenia—Capecitabine—prostate cancer	5.93e-05	0.000274	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CB—prostate cancer	5.93e-05	0.00169	CbGpPWpGaD
Avanafil—Dry mouth—Epirubicin—prostate cancer	5.88e-05	0.000271	CcSEcCtD
Avanafil—Vertigo—Doxorubicin—prostate cancer	5.87e-05	0.000271	CcSEcCtD
Avanafil—Pruritus—Capecitabine—prostate cancer	5.85e-05	0.00027	CcSEcCtD
Avanafil—Diarrhoea—Docetaxel—prostate cancer	5.84e-05	0.000269	CcSEcCtD
Avanafil—Body temperature increased—Prednisone—prostate cancer	5.82e-05	0.000268	CcSEcCtD
Avanafil—Palpitations—Doxorubicin—prostate cancer	5.77e-05	0.000266	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	5.76e-05	0.00164	CbGpPWpGaD
Avanafil—Infection—Epirubicin—prostate cancer	5.72e-05	0.000264	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	5.71e-05	0.00163	CbGpPWpGaD
Avanafil—Cough—Doxorubicin—prostate cancer	5.7e-05	0.000263	CcSEcCtD
Avanafil—Diarrhoea—Capecitabine—prostate cancer	5.66e-05	0.000261	CcSEcCtD
Avanafil—Nervous system disorder—Epirubicin—prostate cancer	5.65e-05	0.00026	CcSEcCtD
Avanafil—Dizziness—Docetaxel—prostate cancer	5.65e-05	0.00026	CcSEcCtD
Avanafil—Hypertension—Doxorubicin—prostate cancer	5.64e-05	0.00026	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	5.63e-05	0.00161	CbGpPWpGaD
Avanafil—Tachycardia—Epirubicin—prostate cancer	5.62e-05	0.000259	CcSEcCtD
Avanafil—Skin disorder—Epirubicin—prostate cancer	5.6e-05	0.000258	CcSEcCtD
Avanafil—Chest pain—Doxorubicin—prostate cancer	5.56e-05	0.000256	CcSEcCtD
Avanafil—Myalgia—Doxorubicin—prostate cancer	5.56e-05	0.000256	CcSEcCtD
Avanafil—Arthralgia—Doxorubicin—prostate cancer	5.56e-05	0.000256	CcSEcCtD
Avanafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.52e-05	0.000255	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA3—prostate cancer	5.52e-05	0.00157	CbGpPWpGaD
Avanafil—Dizziness—Capecitabine—prostate cancer	5.47e-05	0.000252	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	5.46e-05	0.00156	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—IL2—prostate cancer	5.44e-05	0.00155	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	5.44e-05	0.00155	CbGpPWpGaD
Avanafil—Dry mouth—Doxorubicin—prostate cancer	5.44e-05	0.000251	CcSEcCtD
Avanafil—Vomiting—Docetaxel—prostate cancer	5.43e-05	0.00025	CcSEcCtD
Avanafil—Rash—Docetaxel—prostate cancer	5.38e-05	0.000248	CcSEcCtD
Avanafil—Hypotension—Epirubicin—prostate cancer	5.38e-05	0.000248	CcSEcCtD
Avanafil—Dermatitis—Docetaxel—prostate cancer	5.38e-05	0.000248	CcSEcCtD
Avanafil—Headache—Docetaxel—prostate cancer	5.35e-05	0.000247	CcSEcCtD
Avanafil—Infection—Doxorubicin—prostate cancer	5.29e-05	0.000244	CcSEcCtD
Avanafil—Asthenia—Prednisone—prostate cancer	5.28e-05	0.000244	CcSEcCtD
Avanafil—Vomiting—Capecitabine—prostate cancer	5.26e-05	0.000242	CcSEcCtD
Avanafil—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.25e-05	0.000242	CcSEcCtD
Avanafil—Nervous system disorder—Doxorubicin—prostate cancer	5.23e-05	0.000241	CcSEcCtD
Avanafil—Rash—Capecitabine—prostate cancer	5.21e-05	0.00024	CcSEcCtD
Avanafil—Pruritus—Prednisone—prostate cancer	5.21e-05	0.00024	CcSEcCtD
Avanafil—Insomnia—Epirubicin—prostate cancer	5.21e-05	0.00024	CcSEcCtD
Avanafil—Dermatitis—Capecitabine—prostate cancer	5.21e-05	0.00024	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	5.21e-05	0.00148	CbGpPWpGaD
Avanafil—Tachycardia—Doxorubicin—prostate cancer	5.2e-05	0.00024	CcSEcCtD
Avanafil—Headache—Capecitabine—prostate cancer	5.18e-05	0.000239	CcSEcCtD
Avanafil—Skin disorder—Doxorubicin—prostate cancer	5.18e-05	0.000239	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.13e-05	0.00146	CbGpPWpGaD
Avanafil—Somnolence—Epirubicin—prostate cancer	5.12e-05	0.000236	CcSEcCtD
Avanafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.1e-05	0.00146	CbGpPWpGaD
Avanafil—Nausea—Docetaxel—prostate cancer	5.07e-05	0.000234	CcSEcCtD
Avanafil—Dyspepsia—Epirubicin—prostate cancer	5.07e-05	0.000234	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.05e-05	0.00144	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.05e-05	0.00144	CbGpPWpGaD
Avanafil—Diarrhoea—Prednisone—prostate cancer	5.04e-05	0.000232	CcSEcCtD
Avanafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.03e-05	0.00144	CbGpPWpGaD
Avanafil—Hypotension—Doxorubicin—prostate cancer	4.98e-05	0.00023	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	4.98e-05	0.00142	CbGpPWpGaD
Avanafil—Gastrointestinal disorder—Epirubicin—prostate cancer	4.97e-05	0.000229	CcSEcCtD
Avanafil—Fatigue—Epirubicin—prostate cancer	4.97e-05	0.000229	CcSEcCtD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	4.95e-05	0.00141	CbGpPWpGaD
Avanafil—Constipation—Epirubicin—prostate cancer	4.93e-05	0.000227	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTA2—prostate cancer	4.92e-05	0.0014	CbGpPWpGaD
Avanafil—Nausea—Capecitabine—prostate cancer	4.91e-05	0.000226	CcSEcCtD
Avanafil—PDE5A—Hemostasis—EP300—prostate cancer	4.88e-05	0.00139	CbGpPWpGaD
Avanafil—Dizziness—Prednisone—prostate cancer	4.87e-05	0.000225	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	4.86e-05	0.00139	CbGpPWpGaD
Avanafil—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.86e-05	0.000224	CcSEcCtD
Avanafil—Insomnia—Doxorubicin—prostate cancer	4.82e-05	0.000222	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	4.79e-05	0.00137	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—SRC—prostate cancer	4.75e-05	0.00135	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTA1—prostate cancer	4.74e-05	0.00135	CbGpPWpGaD
Avanafil—Somnolence—Doxorubicin—prostate cancer	4.74e-05	0.000218	CcSEcCtD
Avanafil—Dyspepsia—Doxorubicin—prostate cancer	4.69e-05	0.000216	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTO1—prostate cancer	4.69e-05	0.00134	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—NAT2—prostate cancer	4.69e-05	0.00134	CbGpPWpGaD
Avanafil—Vomiting—Prednisone—prostate cancer	4.68e-05	0.000216	CcSEcCtD
Avanafil—Rash—Prednisone—prostate cancer	4.64e-05	0.000214	CcSEcCtD
Avanafil—Dermatitis—Prednisone—prostate cancer	4.64e-05	0.000214	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	4.63e-05	0.00132	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	4.63e-05	0.00132	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—VEGFA—prostate cancer	4.63e-05	0.00132	CbGpPWpGaD
Avanafil—Headache—Prednisone—prostate cancer	4.61e-05	0.000213	CcSEcCtD
Avanafil—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.6e-05	0.000212	CcSEcCtD
Avanafil—Fatigue—Doxorubicin—prostate cancer	4.6e-05	0.000212	CcSEcCtD
Avanafil—Constipation—Doxorubicin—prostate cancer	4.56e-05	0.00021	CcSEcCtD
Avanafil—Body temperature increased—Epirubicin—prostate cancer	4.55e-05	0.00021	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	4.5e-05	0.00128	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	4.44e-05	0.00127	CbGpPWpGaD
Avanafil—Nausea—Prednisone—prostate cancer	4.37e-05	0.000202	CcSEcCtD
Avanafil—PDE5A—Hemostasis—TGFB1—prostate cancer	4.25e-05	0.00121	CbGpPWpGaD
Avanafil—Body temperature increased—Doxorubicin—prostate cancer	4.21e-05	0.000194	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.18e-05	0.00119	CbGpPWpGaD
Avanafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.14e-05	0.00118	CbGpPWpGaD
Avanafil—Asthenia—Epirubicin—prostate cancer	4.13e-05	0.000191	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.12e-05	0.00118	CbGpPWpGaD
Avanafil—Pruritus—Epirubicin—prostate cancer	4.08e-05	0.000188	CcSEcCtD
Avanafil—Diarrhoea—Epirubicin—prostate cancer	3.94e-05	0.000182	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	3.93e-05	0.00112	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—KRAS—prostate cancer	3.93e-05	0.00112	CbGpPWpGaD
Avanafil—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	3.89e-05	0.00111	CbGpPWpGaD
Avanafil—Asthenia—Doxorubicin—prostate cancer	3.82e-05	0.000176	CcSEcCtD
Avanafil—Dizziness—Epirubicin—prostate cancer	3.81e-05	0.000176	CcSEcCtD
Avanafil—Pruritus—Doxorubicin—prostate cancer	3.77e-05	0.000174	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—HPGDS—prostate cancer	3.75e-05	0.00107	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	3.73e-05	0.00106	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	3.68e-05	0.00105	CbGpPWpGaD
Avanafil—Vomiting—Epirubicin—prostate cancer	3.66e-05	0.000169	CcSEcCtD
Avanafil—Diarrhoea—Doxorubicin—prostate cancer	3.65e-05	0.000168	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—GSTT1—prostate cancer	3.64e-05	0.00104	CbGpPWpGaD
Avanafil—Rash—Epirubicin—prostate cancer	3.63e-05	0.000167	CcSEcCtD
Avanafil—Dermatitis—Epirubicin—prostate cancer	3.63e-05	0.000167	CcSEcCtD
Avanafil—PDE5A—Hemostasis—PIK3CA—prostate cancer	3.61e-05	0.00103	CbGpPWpGaD
Avanafil—Headache—Epirubicin—prostate cancer	3.61e-05	0.000166	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	3.6e-05	0.00103	CbGpPWpGaD
Avanafil—Dizziness—Doxorubicin—prostate cancer	3.52e-05	0.000163	CcSEcCtD
Avanafil—PDE5A—Hemostasis—TP53—prostate cancer	3.5e-05	0.000997	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.45e-05	0.000984	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.44e-05	0.000982	CbGpPWpGaD
Avanafil—Nausea—Epirubicin—prostate cancer	3.42e-05	0.000158	CcSEcCtD
Avanafil—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.4e-05	0.000969	CbGpPWpGaD
Avanafil—Vomiting—Doxorubicin—prostate cancer	3.39e-05	0.000156	CcSEcCtD
Avanafil—Rash—Doxorubicin—prostate cancer	3.36e-05	0.000155	CcSEcCtD
Avanafil—Dermatitis—Doxorubicin—prostate cancer	3.36e-05	0.000155	CcSEcCtD
Avanafil—Headache—Doxorubicin—prostate cancer	3.34e-05	0.000154	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.28e-05	0.000936	CbGpPWpGaD
Avanafil—Nausea—Doxorubicin—prostate cancer	3.17e-05	0.000146	CcSEcCtD
Avanafil—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.06e-05	0.000872	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.02e-05	0.00086	CbGpPWpGaD
Avanafil—PDE5A—Hemostasis—AKT1—prostate cancer	2.95e-05	0.000842	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	2.9e-05	0.000827	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	2.86e-05	0.000816	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GGT1—prostate cancer	2.81e-05	0.000801	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—NCOA1—prostate cancer	2.76e-05	0.000789	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	2.73e-05	0.000777	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	2.69e-05	0.000767	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—RXRA—prostate cancer	2.63e-05	0.00075	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—COMT—prostate cancer	2.53e-05	0.000723	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.52e-05	0.000719	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.5e-05	0.000713	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.49e-05	0.000709	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.32e-05	0.000661	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.29e-05	0.000652	CbGpPWpGaD
Avanafil—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.2e-05	0.000627	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HAO1—prostate cancer	2.17e-05	0.000618	CbGpPWpGaD
Avanafil—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.17e-05	0.000618	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ADI1—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TST—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CBR1—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PSAT1—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CSAD—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GRHL1—prostate cancer	1.77e-05	0.000504	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.64e-05	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CKMT2—prostate cancer	1.64e-05	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.64e-05	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GRHPR—prostate cancer	1.64e-05	0.000469	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PGAM2—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAGLU—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—RFK—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM3—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AOX1—prostate cancer	1.54e-05	0.000441	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.46e-05	0.000418	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AMACR—prostate cancer	1.46e-05	0.000418	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—DEGS1—prostate cancer	1.46e-05	0.000418	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAT1—prostate cancer	1.46e-05	0.000418	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.46e-05	0.000418	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.4e-05	0.000399	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HPGD—prostate cancer	1.25e-05	0.000355	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.25e-05	0.000355	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.17e-05	0.000334	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTAP—prostate cancer	1.14e-05	0.000325	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.14e-05	0.000325	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.11e-05	0.000317	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.11e-05	0.000317	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ACSL4—prostate cancer	1.06e-05	0.000302	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.06e-05	0.000302	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UMPS—prostate cancer	1.01e-05	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PHGDH—prostate cancer	1.01e-05	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ARG2—prostate cancer	1.01e-05	0.00029	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LDHB—prostate cancer	9.95e-06	0.000284	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP3A5—prostate cancer	9.77e-06	0.000279	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TCN2—prostate cancer	9.44e-06	0.000269	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA3—prostate cancer	9.44e-06	0.000269	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—UCP3—prostate cancer	9.44e-06	0.000269	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PDHA1—prostate cancer	9.44e-06	0.000269	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD3B1—prostate cancer	9e-06	0.000257	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC22A3—prostate cancer	9e-06	0.000257	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TBXAS1—prostate cancer	8.63e-06	0.000246	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA4—prostate cancer	8.63e-06	0.000246	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA2—prostate cancer	8.41e-06	0.00024	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SULT1A1—prostate cancer	8.31e-06	0.000237	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ABCG5—prostate cancer	8.31e-06	0.000237	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTA1—prostate cancer	8.11e-06	0.000231	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTO1—prostate cancer	8.02e-06	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HSD3B2—prostate cancer	8.02e-06	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NAT2—prostate cancer	8.02e-06	0.000229	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2C18—prostate cancer	7.69e-06	0.000219	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PLCB2—prostate cancer	7.69e-06	0.000219	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LRP2—prostate cancer	7.69e-06	0.000219	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—P4HB—prostate cancer	7.54e-06	0.000215	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC22A1—prostate cancer	7.34e-06	0.000209	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SULT2A1—prostate cancer	7.15e-06	0.000204	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MED12—prostate cancer	7.04e-06	0.000201	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GNG5—prostate cancer	6.98e-06	0.000199	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA3—prostate cancer	6.72e-06	0.000192	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—HPGDS—prostate cancer	6.41e-06	0.000183	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2C19—prostate cancer	6.37e-06	0.000182	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTT1—prostate cancer	6.22e-06	0.000177	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ACHE—prostate cancer	6.22e-06	0.000177	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2A6—prostate cancer	6.15e-06	0.000175	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.98e-06	0.000171	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PRKACB—prostate cancer	5.95e-06	0.00017	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.89e-06	0.000168	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA2—prostate cancer	5.61e-06	0.00016	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.35e-06	0.000153	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.23e-06	0.000149	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NQO1—prostate cancer	5.17e-06	0.000147	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TH—prostate cancer	5.1e-06	0.000145	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.96e-06	0.000141	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GGT1—prostate cancer	4.8e-06	0.000137	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NCOA1—prostate cancer	4.73e-06	0.000135	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.66e-06	0.000133	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—RXRA—prostate cancer	4.5e-06	0.000128	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—COMT—prostate cancer	4.33e-06	0.000124	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTP1—prostate cancer	4.31e-06	0.000123	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ITPR1—prostate cancer	4.24e-06	0.000121	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—TYMS—prostate cancer	4.01e-06	0.000114	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—GSTM1—prostate cancer	3.96e-06	0.000113	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—LPL—prostate cancer	3.89e-06	0.000111	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.76e-06	0.000107	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—ERCC2—prostate cancer	3.73e-06	0.000106	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—MTHFR—prostate cancer	3.5e-06	9.99e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PPARA—prostate cancer	3.44e-06	9.8e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CAV1—prostate cancer	3.23e-06	9.22e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.94e-06	8.39e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—INS—prostate cancer	2.79e-06	7.95e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—CREBBP—prostate cancer	2.73e-06	7.78e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.59e-06	7.38e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—NOS3—prostate cancer	2.44e-06	6.97e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.25e-06	6.43e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTGS2—prostate cancer	2.23e-06	6.37e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PTEN—prostate cancer	1.95e-06	5.56e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—EP300—prostate cancer	1.86e-06	5.3e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.37e-06	3.92e-05	CbGpPWpGaD
Avanafil—CYP3A4—Metabolism—AKT1—prostate cancer	1.12e-06	3.2e-05	CbGpPWpGaD
